Published in J Virol on August 30, 2006
In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol (2008) 3.79
Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther (2011) 2.91
Viral quasispecies evolution. Microbiol Mol Biol Rev (2012) 2.69
Efficient serotype-dependent release of functional vector into the culture medium during adeno-associated virus manufacturing. Hum Gene Ther (2010) 2.19
Structure of adeno-associated virus serotype 8, a gene therapy vector. J Virol (2007) 2.15
Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat Biotechnol (2009) 2.07
Expanded repertoire of AAV vector serotypes mediate unique patterns of transduction in mouse brain. Mol Ther (2008) 2.06
Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol Ther (2011) 1.86
Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J Biol Chem (2011) 1.73
DNA shuffling of adeno-associated virus yields functionally diverse viral progeny. Mol Ther (2008) 1.70
Tropism and toxicity of adeno-associated viral vector serotypes 1, 2, 5, 6, 7, 8, and 9 in rat neurons and glia in vitro. Virology (2007) 1.66
Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol Ther (2009) 1.61
Recombinant adeno-associated virus transduction and integration. Mol Ther (2008) 1.44
Naturally occurring singleton residues in AAV capsid impact vector performance and illustrate structural constraints. Gene Ther (2009) 1.42
Structural characterization of the dual glycan binding adeno-associated virus serotype 6. J Virol (2010) 1.42
Production and titering of recombinant adeno-associated viral vectors. J Vis Exp (2011) 1.41
Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro. Mol Ther (2008) 1.41
A novel adeno-associated viral variant for efficient and selective intravitreal transduction of rat Müller cells. PLoS One (2009) 1.40
Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol Ther (2011) 1.34
AAV9: a potential blood-brain barrier buster. Mol Ther (2009) 1.30
Molecular engineering of viral gene delivery vehicles. Annu Rev Biomed Eng (2008) 1.28
Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS One (2013) 1.24
Adeno-associated virus-2 and its primary cellular receptor--Cryo-EM structure of a heparin complex. Virology (2009) 1.23
Viral vectors: from virology to transgene expression. Br J Pharmacol (2009) 1.19
Glycosaminoglycans and sialylated glycans sequentially facilitate Merkel cell polyomavirus infectious entry. PLoS Pathog (2011) 1.19
A single amino acid substitution in the murine norovirus capsid protein is sufficient for attenuation in vivo. J Virol (2008) 1.19
Comparative analysis of adeno-associated virus capsid stability and dynamics. J Virol (2013) 1.16
High-efficiency transduction of human monocyte-derived dendritic cells by capsid-modified recombinant AAV2 vectors. Vaccine (2012) 1.12
Production, purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 1. Acta Crystallogr Sect F Struct Biol Cryst Commun (2006) 1.12
Immune responses to AAV in canine muscle monitored by cellular assays and noninvasive imaging. Mol Ther (2009) 1.11
Specific AAV serotypes stably transduce primary hippocampal and cortical cultures with high efficiency and low toxicity. Brain Res (2007) 1.07
Structure-function analysis of receptor-binding in adeno-associated virus serotype 6 (AAV-6). Virology (2011) 1.05
Biology of adeno-associated viral vectors in the central nervous system. Front Mol Neurosci (2014) 1.04
Drawing a high-resolution functional map of adeno-associated virus capsid by massively parallel sequencing. Nat Commun (2014) 1.04
Structural studies of adeno-associated virus serotype 8 capsid transitions associated with endosomal trafficking. J Virol (2011) 1.04
Surface loop dynamics in adeno-associated virus capsid assembly. J Virol (2008) 1.04
Efficient transduction and optogenetic stimulation of retinal bipolar cells by a synthetic adeno-associated virus capsid and promoter. EMBO Mol Med (2014) 1.04
Capsid antibodies to different adeno-associated virus serotypes bind common regions. J Virol (2013) 1.01
Structure and dynamics of adeno-associated virus serotype 1 VP1-unique N-terminal domain and its role in capsid trafficking. J Virol (2013) 1.01
Structures of Merkel cell polyomavirus VP1 complexes define a sialic acid binding site required for infection. PLoS Pathog (2012) 1.01
Human galectin 3 binding protein interacts with recombinant adeno-associated virus type 6. J Virol (2012) 0.99
Engraftment of a galactose receptor footprint onto adeno-associated viral capsids improves transduction efficiency. J Biol Chem (2013) 0.96
Production, purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 7. Acta Crystallogr Sect F Struct Biol Cryst Commun (2007) 0.95
AAV vectors containing rDNA homology display increased chromosomal integration and transgene persistence. Mol Ther (2012) 0.93
Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5. J Gen Virol (2011) 0.93
Characterization of interactions between heparin/glycosaminoglycan and adeno-associated virus. Biochemistry (2013) 0.93
Structural insights into adeno-associated virus serotype 5. J Virol (2013) 0.92
Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942). J Virol (2008) 0.92
AAV ancestral reconstruction library enables selection of broadly infectious viral variants. Gene Ther (2015) 0.91
Intramuscular AAV delivery of NT-3 alters synaptic transmission to motoneurons in adult rats. Eur J Neurosci (2010) 0.91
Parvovirus glycan interactions. Curr Opin Virol (2014) 0.90
Twinned crystals of adeno-associated virus serotype 3b prove suitable for structural studies. Acta Crystallogr Sect F Struct Biol Cryst Commun (2009) 0.89
An emerging adeno-associated viral vector pipeline for cardiac gene therapy. Hum Gene Ther (2013) 0.88
Progresses towards safe and efficient gene therapy vectors. Oncotarget (2015) 0.88
Crystallization and preliminary X-ray structural studies of adeno-associated virus serotype 6. Acta Crystallogr Sect F Struct Biol Cryst Commun (2008) 0.88
Heparin-binding correlates with increased efficiency of AAV1- and AAV6-mediated transduction of striated muscle, but negatively impacts CNS transduction. Gene Ther (2012) 0.88
Multiple roles for sialylated glycans in determining the cardiopulmonary tropism of adeno-associated virus 4. J Virol (2013) 0.87
Efficient gene delivery and selective transduction of astrocytes in the mammalian brain using viral vectors. Front Cell Neurosci (2013) 0.86
Impact of Heparan Sulfate Binding on Transduction of Retina by Recombinant Adeno-Associated Virus Vectors. J Virol (2016) 0.85
Three amino acid mutations (F51L, T59A, and S390L) in the capsid protein of the hepatitis E virus collectively contribute to virus attenuation. J Virol (2011) 0.85
AAV-6 mediated efficient transduction of mouse lower airways. Virology (2011) 0.84
Targeted gene delivery to the enteric nervous system using AAV: a comparison across serotypes and capsid mutants. Mol Ther (2015) 0.84
Improved adeno-associated virus (AAV) serotype 1 and 5 vectors for gene therapy. Sci Rep (2013) 0.84
Sites in the AAV5 capsid tolerant to deletions and tandem duplications. Arch Biochem Biophys (2010) 0.83
C-reactive protein (CRP) is essential for efficient systemic transduction of recombinant adeno-associated virus vector 1 (rAAV-1) and rAAV-6 in mice. J Virol (2013) 0.82
Distinct transduction difference between adeno-associated virus type 1 and type 6 vectors in human polarized airway epithelia. Gene Ther (2012) 0.82
Adeno-associated Virus as a Mammalian DNA Vector. Microbiol Spectr (2015) 0.82
Single point mutation in adeno-associated viral vectors -DJ capsid leads to improvement for gene delivery in vivo. BMC Biotechnol (2016) 0.82
Identification and mutagenesis of the adeno-associated virus 5 sialic acid binding region. J Virol (2014) 0.80
Novel adeno-associated viruses derived from pig tissues transduce most major organs in mice. Sci Rep (2014) 0.80
Improving clinical efficacy of adeno associated vectors by rational capsid bioengineering. J Biomed Sci (2014) 0.80
Characterization of the Adeno-Associated Virus 1 and 6 Sialic Acid Binding Site. J Virol (2016) 0.79
Electron microscopy analysis of a disaccharide analog complex reveals receptor interactions of adeno-associated virus. J Struct Biol (2013) 0.79
Heparan Sulfate Binding Promotes Accumulation of Intravitreally Delivered Adeno-associated Viral Vectors at the Retina for Enhanced Transduction but Weakly Influences Tropism. J Virol (2016) 0.78
Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids. Methods Mol Biol (2016) 0.77
Structure of neurotropic adeno-associated virus AAVrh.8. J Struct Biol (2015) 0.77
Profiling of glycan receptors for minute virus of mice in permissive cell lines towards understanding the mechanism of cell recognition. PLoS One (2014) 0.76
Gene delivery to rat and human Schwann cells and nerve segments: a comparison of AAV 1-9 and lentiviral vectors. Gene Ther (2015) 0.76
Recombinant Adeno-Associated Virus Serotype 6 (rAAV6) Potently and Preferentially Transduces Rat Astrocytes In vitro and In vivo. Front Cell Neurosci (2016) 0.75
Unique glycan signatures regulate adeno-associated virus tropism in the developing brain. J Virol (2015) 0.75
Scalable downstream strategies for purification of recombinant adeno- associated virus vectors in light of the properties. Curr Pharm Biotechnol (2015) 0.75
Recombinant adeno-associated viral (rAAV) vectors mediate efficient gene transduction in cultured neonatal and adult microglia. J Neurochem (2015) 0.75
Recombinant adeno-associated virus serotype 6 efficiently transduces primary human melanocytes. PLoS One (2013) 0.75
Analysis of Evolutionary Processes of Species Jump in Waterfowl Parvovirus. Front Microbiol (2017) 0.75
Development of novel AAV serotype 6 based vectors with selective tropism for human cancer cells. Gene Ther (2015) 0.75
Nanotherapy for Duchenne muscular dystrophy. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2017) 0.75
Thermal Stability as a Determinant of AAV Serotype Identity. Mol Ther Methods Clin Dev (2017) 0.75
SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res (2003) 25.86
Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol (1998) 8.45
Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol (1998) 7.76
Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol (2002) 5.82
Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol (1998) 4.71
Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther (2006) 4.36
The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci U S A (2002) 4.30
Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat Biotechnol (2006) 4.12
Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol (2000) 3.27
Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J Virol (2003) 3.25
Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem (2001) 3.15
Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J Virol (2001) 3.11
Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors. J Virol (2001) 2.95
Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol (2003) 2.93
Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J Virol (2006) 2.79
Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood (2003) 2.74
Mutations on the external surfaces of adeno-associated virus type 2 capsids that affect transduction and neutralization. J Virol (2006) 2.07
Intracellular trafficking of adeno-associated viral vectors. Gene Ther (2005) 1.95
AAV hybrid serotypes: improved vectors for gene delivery. Curr Gene Ther (2005) 1.80
Successful expression of human factor IX following repeat administration of adenoviral vector in mice. Proc Natl Acad Sci U S A (1996) 1.55
Combinations of two capsid regions controlling canine host range determine canine transferrin receptor binding by canine and feline parvoviruses. J Virol (2003) 1.48
Structure of adeno-associated virus type 4. J Virol (2005) 1.47
The use of adeno-associated virus to circumvent the maturation-dependent viral transduction of muscle fibers. Hum Gene Ther (2000) 1.14
Host-selected amino acid changes at the sialic acid binding pocket of the parvovirus capsid modulate cell binding affinity and determine virulence. J Virol (2006) 1.05
Targeted delivery of plasmid DNA to hepatocytes in vivo: optimization of the pharmacokinetics of plasmid DNA/galactosylated poly(L-lysine) complexes by controlling their physicochemical properties. J Pharmacol Exp Ther (1998) 0.96
Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol (2002) 5.82
Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol Ther (2006) 4.36
Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med (2010) 4.28
Production and characterization of adeno-associated viral vectors. Nat Protoc (2006) 4.11
Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A (2008) 3.84
Investigation of the cause of death in a gene-therapy trial. N Engl J Med (2009) 3.02
Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol (2003) 2.93
Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates. Mol Ther (2011) 2.91
Alpha2,3 and alpha2,6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J Virol (2006) 2.79
Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat Med (2003) 2.70
The AAV vector toolkit: poised at the clinical crossroads. Mol Ther (2012) 2.53
Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet (2004) 2.36
Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol Ther (2008) 2.19
Structure of adeno-associated virus serotype 8, a gene therapy vector. J Virol (2007) 2.15
The family Parvoviridae. Arch Virol (2013) 2.12
Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy. Nat Med (2005) 2.10
Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat Biotechnol (2009) 2.07
Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther (2011) 2.04
Entrapment of carbon dioxide in the active site of carbonic anhydrase II. J Biol Chem (2008) 1.98
Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. J Virol (2006) 1.97
Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology (2008) 1.96
Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum Gene Ther (2011) 1.90
Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol Ther (2011) 1.86
A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc Natl Acad Sci U S A (2009) 1.85
Atomic crystal and molecular dynamics simulation structures of human carbonic anhydrase II: insights into the proton transfer mechanism. Biochemistry (2007) 1.83
AAV hybrid serotypes: improved vectors for gene delivery. Curr Gene Ther (2005) 1.80
Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther (2010) 1.77
A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis. Mol Ther (2007) 1.75
Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. J Biol Chem (2011) 1.73
Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX. Blood (2008) 1.72
Speeding up proton transfer in a fast enzyme: kinetic and crystallographic studies on the effect of hydrophobic amino acid substitutions in the active site of human carbonic anhydrase II. Biochemistry (2007) 1.72
Structural and kinetic characterization of active-site histidine as a proton shuttle in catalysis by human carbonic anhydrase II. Biochemistry (2005) 1.69
Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups. J Virol (2004) 1.64
Adeno-associated virus type 2 contains an integrin alpha5beta1 binding domain essential for viral cell entry. J Virol (2006) 1.64
Directed evolution of a novel adeno-associated virus (AAV) vector that crosses the seizure-compromised blood-brain barrier (BBB). Mol Ther (2009) 1.61
The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice. J Clin Invest (2011) 1.58
Gene therapy for rare diseases: summary of a National Institutes of Health workshop, September 13, 2012. Hum Gene Ther (2013) 1.54
Cellular immune response to cryptic epitopes during therapeutic gene transfer. Proc Natl Acad Sci U S A (2009) 1.53
Comparison of adeno-associated viral vector serotypes for spinal cord and motor neuron gene delivery. Hum Gene Ther (2011) 1.53
Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo. J Virol (2007) 1.52
Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material. Hum Gene Ther (2010) 1.51
Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus. J Virol (2008) 1.50
Structure of adeno-associated virus serotype 5. J Virol (2004) 1.50
Combinations of two capsid regions controlling canine host range determine canine transferrin receptor binding by canine and feline parvoviruses. J Virol (2003) 1.48
Structure of adeno-associated virus type 4. J Virol (2005) 1.47
Heparin binding induces conformational changes in Adeno-associated virus serotype 2. J Struct Biol (2008) 1.44
Host cell DNA repair pathways in adeno-associated viral genome processing. J Virol (2006) 1.43
Structural characterization of the dual glycan binding adeno-associated virus serotype 6. J Virol (2010) 1.42
Structural determinants of tissue tropism and in vivo pathogenicity for the parvovirus minute virus of mice. J Virol (2005) 1.41
The refined atomic structure of carbonic anhydrase II at 1.05 A resolution: implications of chemical rescue of proton transfer. Acta Crystallogr D Biol Crystallogr (2002) 1.39
A short, strong hydrogen bond in the active site of human carbonic anhydrase II. Biochemistry (2010) 1.33
Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors. PLoS One (2013) 1.33
The role of the adeno-associated virus capsid in gene transfer. Methods Mol Biol (2008) 1.29
Bocavirus episome in infected human tissue contains non-identical termini. PLoS One (2011) 1.29
Adeno-associated virus capsid structure drives CD4-dependent CD8+ T cell response to vector encoded proteins. J Immunol (2009) 1.28
Comparing the accumulation of active- and nonactive-site mutations in the HIV-1 protease. Biochemistry (2004) 1.28
Comparative transduction efficiency of AAV vector serotypes 1-6 in the substantia nigra and striatum of the primate brain. Mol Ther (2009) 1.28
Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3. Hum Gene Ther (2010) 1.26
Microviridae, a family divided: isolation, characterization, and genome sequence of phiMH2K, a bacteriophage of the obligate intracellular parasitic bacterium Bdellovibrio bacteriovorus. J Bacteriol (2002) 1.24
Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: the final threshold? PLoS One (2013) 1.24
Marker rescue of adeno-associated virus (AAV) capsid mutants: a novel approach for chimeric AAV production. J Virol (2003) 1.24
Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application. Mol Ther (2010) 1.24
Long-term follow-up after gene therapy for canavan disease. Sci Transl Med (2012) 1.22
Mutagenesis of adeno-associated virus type 2 capsid protein VP1 uncovers new roles for basic amino acids in trafficking and cell-specific transduction. J Virol (2010) 1.21
p37 Induces tumor invasiveness. Mol Cancer Ther (2005) 1.21
Adeno-associated virus (AAV) gene therapy for neurological disease. Neuropharmacology (2012) 1.21
Viral vectors for gene delivery to the central nervous system. Neurobiol Dis (2011) 1.20
Adeno-associated virus vectorology, manufacturing, and clinical applications. Methods Enzymol (2012) 1.19
Structural insight into the unique properties of adeno-associated virus serotype 9. J Virol (2012) 1.18
Generation of novel AAV variants by directed evolution for improved CFTR delivery to human ciliated airway epithelium. Mol Ther (2009) 1.18
Identification of the sialic acid structures recognized by minute virus of mice and the role of binding affinity in virulence adaptation. J Biol Chem (2006) 1.17
Structure determination of the cancer-associated Mycoplasma hyorhinis protein Mh-p37. Acta Crystallogr D Biol Crystallogr (2008) 1.17